Of all ARMS patients, approximately 60% express PAX3-FOXO1, 20% express PAX7-FOXO1, 20% are fusion negative (11, 12), and a small subset express rare variants such as PAX3-FOXO4 or PAX3-NOXA1 (12). This evidence concerns the gene FOXO1 and alveolar rhabdomyosarcoma.